title: Novel treatments for cardiovascular disease prevention.
abstract: The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.
authors: Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. m-huffman@northwestern.edu
authors: Mark D
authors: MD
authors: Huffman
authors: Deepak
authors: D
authors: Bhatnagar
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D020517:Atrial Appendage / Q000502:physiology; D031204:Caloric Restriction; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D019411:Clinical Laboratory Techniques; D003153:Community Health Services; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016540:Smoking Cessation
chemical_list: D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors